MIA PaCa-2 Cells
Basic details about the Mia Paca-2 cell line
Description | The MIA PaCa-2 cell line is an indispensable asset in the field of cancer research and was derived from the pancreatic carcinoma tissue of a 65-year-old male. Mia PaCa 2 cells are widely used in the study of pancreatic ductal adenocarcinoma (PDAC), a notoriously aggressive and lethal cancer type. The cell line offer a solid tumor model that reflects the cellular characteristics of PDAC. One of the key attributes of this cell line is its genetic profile, which includes mutations in critical genes like KRAS and TP53, which are emblematic of the genetic landscape observed in pancreatic cancer patients. The cells have been extensively utilized to investigate various aspects of pancreatic cancer growth, metastasis, and resistance to therapeutics. Mia Paca-2 cells are instrumental in assessing the efficacy of chemotherapeutic drugs. Furthermore, the cell line serves as a vital resource for probing into the signaling pathways pivotal for cancer cell survival and metastasis, including the MAPK, PI3K/AKT, and Wnt pathways. Studies utilizing MIA PaCa-2 cells have also shed light on the dynamic interactions between cancer cells and their microenvironment. MIA PaCa-2's robust in vitro growth and its capacity to form tumors in xenograft models make it particularly suited for examining cancer progression and the mechanisms of tumorigenesis. In summary, the Mia Paca-2 cell line, with its broad application in pancreatic cancer research, continues to be a critical resource for scientists worldwide. |
---|---|
Organism | Human |
Tissue | Pancreas |
Disease | Ductal adenocarcinoma |
Synonyms | MIA-PaCa-2, MIA-PACA-2, MIA-Pa-Ca-2, MIA Paca2, MIA PaCa2, MiaPaCa-2, MIAPACA-2, MiaPaca.2, MiaPaCa2, Miapaca2, MIAPaCa2, MIAPACA2, Mia PACA 2, MIAPaCa-2, PaCa2 |
Aspects
Age | 65 years |
---|---|
Gender | Male |
Ethnicity | Caucasian |
Morphology | Epithelial-like |
Growth properties | Adherent with loosely attached rounded cells |
Documentation
Citation | MIA PaCa-2 (Cytion catalog number 300438) |
---|---|
Biosafety level | 1 |
Genetic profile of the ductal adenocarcinoma cell line Mia Paca-2
Isoenzymes | G6PD, B |
---|---|
Tumorigenic | Growth in soft agar. Formation of progressively growing carcinomas in nude athymic mice. |
Mutational profile | Homozygous for KRAS p.Gly12Cys (c.34G>T) Homozygous for CDKN2A deletion |
Karyotype | hypotriploid |
Culturing methods
Culture Medium | DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 1.5 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Passaging solution | Accutase |
Doubling time | 25 to 40 hours |
Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
Split ratio | A ratio of 1:10 is recommended |
Seeding density | 1 x 10^4 cells/cm^2 |
Fluid renewal | 2 to 3 times per week |
Freezing recovery | After thawing, plate the cells at 2 to 5 x 10^4 cells/cm^2 and allow the cells to recover from the freezing process and to adhere for at least 24 hours. |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Purity and identity checks for the pancreatic cancer cell line Mia Paca 2
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile |
Amelogenin: x,x
CSF1PO: 10
D13S317: 12,13
D16S539: 10,13
D5S818: 12,13
D7S820: 12,13
TH01: 9,10
TPOX: 9
vWA: 15
D3S1358: 16
D21S11: 29,31.2
D18S51: 12
D8S1179: 16
FGA: 22
D2S1338: 25
D19S433: 15
|
HLA alleles |
A*: 01.01.1900 00:02
B*: 14:02:01
C*: 08:02:01
DRB1*: 01:02:01
DQA1*: 01:01:02
DQB1*: 05:01:01
DPB1*: 02:01:02
E: 01:01:01
|